|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1998-10-27
|
|
pubmed:abstractText |
Using chemotherapy as a part of each treatment fraction remains unexplored. This study integrates the concomitant administration of carboplatin with hyperfractionated irradiation by optimizing chemopotentiation through carboplatin administration with each irradiation fraction.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1043-3074
|
|
pubmed:author |
pubmed-author:ArtazkozJ JJJ,
pubmed-author:EspiñeiraMM,
pubmed-author:FuentesCC,
pubmed-author:Gil-CurbeloJJ,
pubmed-author:HernandezRR,
pubmed-author:MartinJ JJJ,
pubmed-author:MartinezJ CJC,
pubmed-author:PerezM DMD,
pubmed-author:SaavedraJ AJA,
pubmed-author:SuñerMM,
pubmed-author:VillarAA,
pubmed-author:de SerdioJ LJL
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
489-96
|
|
pubmed:dateRevised |
2006-10-5
|
|
pubmed:meshHeading |
pubmed-meshheading:9702534-Adult,
pubmed-meshheading:9702534-Aged,
pubmed-meshheading:9702534-Antineoplastic Agents,
pubmed-meshheading:9702534-Carboplatin,
pubmed-meshheading:9702534-Carcinoma, Squamous Cell,
pubmed-meshheading:9702534-Combined Modality Therapy,
pubmed-meshheading:9702534-Disease-Free Survival,
pubmed-meshheading:9702534-Dose Fractionation,
pubmed-meshheading:9702534-Drug Administration Schedule,
pubmed-meshheading:9702534-Female,
pubmed-meshheading:9702534-Follow-Up Studies,
pubmed-meshheading:9702534-Head and Neck Neoplasms,
pubmed-meshheading:9702534-Humans,
pubmed-meshheading:9702534-Male,
pubmed-meshheading:9702534-Middle Aged,
pubmed-meshheading:9702534-Neoplasm Staging,
pubmed-meshheading:9702534-Pilot Projects,
pubmed-meshheading:9702534-Survival Rate,
pubmed-meshheading:9702534-Treatment Outcome
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Chemotherapy as a part of each treatment fraction in a twice-a-day hyperfractionated schedule: a new chemoradiotherapy approach for advanced head and neck cancer.
|
|
pubmed:affiliation |
Servicio de Otorrinolaringologia, Hospital de la Candelaria, Santa Cruz de Tenerife, Spain.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
